Market share in Indian open-system molecular diagnostics
12-15%
flat
Company estimates its share of the ₹400-500 crore addressable market.
3BBLACKBIODX
Other
10 Feb 2026
3B Blackbio DX Ltd — Q3 FY26
3B Blackbio reported 9-month revenue of ₹99.06 crore, up 11.8% YoY (or ~20% excluding seasonal flu spikes).
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
3B Blackbio reported 9-month revenue of ₹99.06 crore, up 11.8% YoY (or ~20% excluding seasonal flu spikes). Excluding a one-off HAT contract of ~₹8.8 crore, core growth was modest. Management guided full-year top-line growth of 10-15% and export growth of 15-20%, with EBITDA margin likely compressed due to one-time M&A expenses. The company maintains a 12-15% market share in the Indian open-system molecular diagnostics market (TAM ₹400-500 crore). Key growth drivers include the Chorus acquisition (lateral flow/AMR), UK subsidiary expansion, and upcoming US FDA filings for Chorus products. Risks include intensifying competition from players entering high-margin molecular diagnostics, lumpy HAT contract sunsetting in 2 years, and slow NGS adoption. The company is actively scouting for acquisitions with ~₹130-140 crore earmarked.
Key Numbers
Export growth rate (9M FY26)
26%
+26% YoY
Exports grew 26% in 9M, driven by UK subsidiary and PCR Europe.
HAT contract revenue (Q3 FY26)
₹8.8 crore
one-off
One-off revenue from WHO HAT contract; expected to continue at ~$1.5M/year for 2 more years.
Number of countries exported to
70
flat
Company exports to 70 countries through PCR Europe and other channels.
Management Guidance
Full-year revenue growth 10-15%
Management expects overall top-line growth of 10-15% for FY26, excluding one-off items.
Management guidance revenueExport growth 15-20% for FY26
Exports are expected to grow 15-20% in FY26, driven by UK subsidiary and new registrations.
Management guidance growthChorus EBITDA positive at 2-4% next year
Chorus is targeted to become EBITDA positive at 2-4% of revenue in the next fiscal year.
Management guidance marginsSample-to-answer machine launch next quarter
A new sample-to-answer system (OEM) is expected to be launched in the next quarter, targeting infection and oncology segments.
Management guidance expansionKey Risks
Increasing competition in molecular diagnostics
New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.
high · management_commentaryHAT contract sunset risk
The WHO HAT contract (~$1.5M/year) will end in ~2 years; replacement revenue from US FDA is uncertain.
medium · analyst_questionSlow NGS adoption and low margins
NGS segment has low margins and slow traction; management views it as a technology hedge rather than a growth driver.
low · management_commentaryCredit period extension impacting cash flow
Industry credit periods have extended to 3-5 months, matching competitors, which could pressure working capital.
medium · analyst_questionNotable Quotes
We are already doing a sample to answer machine... So once we have this sample to answer machine probably in the next quarter, this will have a different segment to be added.
US is a must to have.
We are very actively looking... we have appointed two consultants, we ourselves dedicate almost one hour or two hours searching for company that is the top of the agenda to acquire a company.
Frequently Asked Questions
What was 3B Blackbio DX's revenue in Q3 FY26?
3B Blackbio DX reported revenue of ₹50 Cr in Q3 FY26, representing a +11.8% change compared to the same quarter last year.
What guidance did 3B Blackbio DX management give for FY27?
Full-year revenue growth 10-15%: Management expects overall top-line growth of 10-15% for FY26, excluding one-off items. Export growth 15-20% for FY26: Exports are expected to grow 15-20% in FY26, driven by UK subsidiary and new registrations. Chorus EBITDA positive at 2-4% next year: Chorus is targeted to become EBITDA positive at 2-4% of revenue in the next fiscal year. Sample-to-answer machine launch next quarter: A new sample-to-answer system (OEM) is expected to be launched in the next quarter, targeting infection and oncology segments.
What are the key risks for 3B Blackbio DX in FY27?
Key risks include Increasing competition in molecular diagnostics — New entrants from biochemistry/ELISA are entering molecular diagnostics due to high margins, pressuring pricing and market share.; HAT contract sunset risk — The WHO HAT contract (~$1.5M/year) will end in ~2 years; replacement revenue from US FDA is uncertain.; Slow NGS adoption and low margins — NGS segment has low margins and slow traction; management views it as a technology hedge rather than a growth driver.; Credit period extension impacting cash flow — Industry credit periods have extended to 3-5 months, matching competitors, which could pressure working capital..
Did 3B Blackbio DX meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full 3B Blackbio DX Q3 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.